Brainstorm Cell Therapeutics, Inc. (BCLI)
0.75
+0.03
(+4.02%)
USD |
OTCM |
May 29, 16:00
Brainstorm Cell Therapeutics Debt to Equity Ratio : -0.1352 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovelStem International Corp. | -0.8348 |
| Summit Therapeutics, Inc. | 0.0367 |
| Kezar Life Sciences, Inc. | 0.0208 |
| Protara Therapeutics, Inc. | 0.0169 |
| Clene, Inc. | -1.172 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.755M |
| Total Liabilities (Quarterly) | 11.76M |
| Shareholders Equity (Quarterly) | -11.01M |
| Current Ratio | 0.0156 |
| Net Debt Paydown Yield | -0.89% |